WO2011024172A3 - Liposomal compositions and uses of same - Google Patents
Liposomal compositions and uses of same Download PDFInfo
- Publication number
- WO2011024172A3 WO2011024172A3 PCT/IL2010/000703 IL2010000703W WO2011024172A3 WO 2011024172 A3 WO2011024172 A3 WO 2011024172A3 IL 2010000703 W IL2010000703 W IL 2010000703W WO 2011024172 A3 WO2011024172 A3 WO 2011024172A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- same
- liposomal compositions
- liposomes
- compositions
- encapsulate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/392,575 US9642817B2 (en) | 2009-08-27 | 2010-08-26 | Liposomal compositions and uses of same |
EP10761069.3A EP2470164B1 (en) | 2009-08-27 | 2010-08-26 | Liposomal compositions and uses of same |
CN201080048954XA CN102596179A (en) | 2009-08-27 | 2010-08-26 | Liposomal compositions and uses of same |
US15/498,526 US10292933B2 (en) | 2009-08-27 | 2017-04-27 | Liposomal compositions and uses of same |
US16/372,449 US11065203B2 (en) | 2009-08-27 | 2019-04-02 | Liposomal compositions and uses of same |
US17/316,749 US20210267892A1 (en) | 2009-08-27 | 2021-05-11 | Liposomal compositions and uses of same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23730609P | 2009-08-27 | 2009-08-27 | |
US61/237,306 | 2009-08-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/392,575 A-371-Of-International US9642817B2 (en) | 2009-08-27 | 2010-08-26 | Liposomal compositions and uses of same |
US15/498,526 Continuation US10292933B2 (en) | 2009-08-27 | 2017-04-27 | Liposomal compositions and uses of same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011024172A2 WO2011024172A2 (en) | 2011-03-03 |
WO2011024172A3 true WO2011024172A3 (en) | 2011-05-26 |
Family
ID=43618635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2010/000703 WO2011024172A2 (en) | 2009-08-27 | 2010-08-26 | Liposomal compositions and uses of same |
Country Status (4)
Country | Link |
---|---|
US (4) | US9642817B2 (en) |
EP (1) | EP2470164B1 (en) |
CN (2) | CN106619515A (en) |
WO (1) | WO2011024172A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2020221E (en) * | 2007-06-19 | 2012-05-30 | Neubourg Skin Care Gmbh & Co Kg | Dms (derma membrane structure) in foaming creams |
CN106619515A (en) | 2009-08-27 | 2017-05-10 | 工业研究与发展基金会有限公司 | Liposomal compositions and uses of same |
WO2011116237A1 (en) * | 2010-03-17 | 2011-09-22 | Board Of Regents Of The University Of Texas System | Universal cell-directed theranostics |
IT1401457B1 (en) * | 2010-06-11 | 2013-07-26 | Fond I R C C S Istituto Neurologico Carlo Besta | CARRIER OF CELL TYPE FOR THE SIGHTED TRANSPORT OF AT LEAST ONE MOLECULE AND / OR AT LEAST A MOLECULAR COMPOUND AT LEAST ONE TARGET CELL IN A HUMAN OR NON-HUMAN MAMMALY |
US10888625B2 (en) * | 2012-10-30 | 2021-01-12 | Particle Sciences, Inc. | Drug delivery particle formulations with targeting moieties |
CN105143441B (en) * | 2014-01-13 | 2019-11-08 | 张明杰 | Use preparation and its application method of the ghost with active factors as culture in vitro of lymphocytes synergist |
EP3334343B1 (en) * | 2015-08-13 | 2022-10-19 | Takeda Pharmaceutical Company Limited | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation |
JP6289705B1 (en) * | 2017-03-31 | 2018-03-07 | Jsr株式会社 | Method for producing probe binding carrier, probe binding carrier and method for detecting or separating target substance |
BR112019023323A2 (en) | 2017-05-08 | 2020-07-21 | Flagship Pioneering Innovations V, Inc. | compositions to facilitate membrane fusion and uses thereof |
EP3658125A4 (en) * | 2017-07-28 | 2021-04-28 | National University of Singapore | Biomolecular composites comprising modified cell ghosts |
WO2019161281A1 (en) | 2018-02-17 | 2019-08-22 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
WO2020023436A1 (en) * | 2018-07-23 | 2020-01-30 | Campbell Robert B | Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy |
CN110215514B (en) * | 2019-04-22 | 2023-09-05 | 上海瑞可新生物科技有限公司 | Genetically engineered cell membrane nano vesicle and preparation and application thereof |
CN112716915A (en) * | 2021-02-03 | 2021-04-30 | 中国药科大学 | Bionic nano-carrier and application thereof in preparing medicament for treating brain glioma |
CN112957459B (en) * | 2021-02-07 | 2022-10-28 | 天津大学 | Tumor combined immune nano-particles based on influenza virus, preparation method thereof and application thereof in preparing nano-vaccine |
WO2022264129A1 (en) | 2021-06-13 | 2022-12-22 | Nano Ghost Ltd | Compositions comprising spherical particles and uses of same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120797A (en) * | 1996-10-15 | 2000-09-19 | The Liposome Company, Inc. | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
JP2874751B2 (en) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | Transgenic animals secreting the desired protein into milk |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US20110003008A1 (en) * | 2008-02-22 | 2011-01-06 | Agency For Science, Technology And Research (A*Star) | Mesenchymal stem cell particles |
CN106619515A (en) | 2009-08-27 | 2017-05-10 | 工业研究与发展基金会有限公司 | Liposomal compositions and uses of same |
-
2010
- 2010-08-26 CN CN201610416895.6A patent/CN106619515A/en active Pending
- 2010-08-26 US US13/392,575 patent/US9642817B2/en active Active
- 2010-08-26 WO PCT/IL2010/000703 patent/WO2011024172A2/en active Application Filing
- 2010-08-26 CN CN201080048954XA patent/CN102596179A/en active Pending
- 2010-08-26 EP EP10761069.3A patent/EP2470164B1/en active Active
-
2017
- 2017-04-27 US US15/498,526 patent/US10292933B2/en active Active
-
2019
- 2019-04-02 US US16/372,449 patent/US11065203B2/en active Active
-
2021
- 2021-05-11 US US17/316,749 patent/US20210267892A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120797A (en) * | 1996-10-15 | 2000-09-19 | The Liposome Company, Inc. | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
Non-Patent Citations (2)
Title |
---|
IMMORDINO MARIA LAURA ET AL: "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", INTERNATIONAL JOURNAL OF NANOMEDICINE, DOVE MEDICAL PRESS LTD, AUCKLAND, NZ, vol. 1, no. 3, 1 January 2006 (2006-01-01), pages 297 - 315, XP009145524, ISSN: 1176-9114 * |
WESTERMAN LARRY E ET AL: "Liposomes composed of reconstituted membranes for induction of tumor-specific immunity", METHODS IN ENZYMOLOGY; [METHODS IN ENZYMOLOGY], ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 373, 1 January 2003 (2003-01-01), pages 118 - 127, XP009145463, ISSN: 0076-6879 * |
Also Published As
Publication number | Publication date |
---|---|
CN106619515A (en) | 2017-05-10 |
US20120164214A1 (en) | 2012-06-28 |
US20190224125A1 (en) | 2019-07-25 |
EP2470164A2 (en) | 2012-07-04 |
US20170224618A1 (en) | 2017-08-10 |
EP2470164B1 (en) | 2017-05-31 |
US20210267892A1 (en) | 2021-09-02 |
US11065203B2 (en) | 2021-07-20 |
WO2011024172A2 (en) | 2011-03-03 |
US9642817B2 (en) | 2017-05-09 |
CN102596179A (en) | 2012-07-18 |
US10292933B2 (en) | 2019-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011024172A3 (en) | Liposomal compositions and uses of same | |
WO2011106109A3 (en) | Nanotape and nanocarpet materials | |
WO2010111409A3 (en) | Pluripotent stem cells | |
WO2008085221A3 (en) | Therapeutic use of cd31 expressing cells | |
WO2008132229A3 (en) | Highly concentrated insulin solutions and compositions | |
WO2011107462A3 (en) | Sun protection compositions | |
WO2012024452A3 (en) | Modified relaxin polypeptides and their uses | |
EP2659956A4 (en) | Composite semipermeable membrane | |
EP2165694B8 (en) | Vesicle useful for external preparation for skin, and external preparation for skin comprising the vesicle | |
EP2660917A4 (en) | Unit cell of metal-supported solid oxide fuel cell, preparation method thereof, and solid oxide fuel cell stack using the unit cell | |
EP2190307A4 (en) | Preparation method of vegetable extract ferment solution and vegetable extract ferment solution prepared by the same | |
EP2361303B8 (en) | An isolated multipotent mesenchymal stem cell from human adult glomeruli (hgl-msc), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney | |
WO2010111659A8 (en) | Tumor-initiating cells and methods for using same | |
EP2484336A4 (en) | Pigment for cosmetic preparations, method for producing same, and cosmetic preparation containing the pigment for cosmetic preparations | |
ZA201209738B (en) | Levoisovalerylspiramycin i,ii,iii and preparations,preparation methods and uses thereof | |
EP2262039B8 (en) | Battery separator and battery using the same | |
EP2404591A4 (en) | Cosmetic preparation, method for producing same, composition for cosmetic preparations, cosmetic preparation containing the composition for cosmetic preparations and method for producing same, and cleanser for industrial use | |
WO2012024350A3 (en) | Anti-cancer adenoviruses | |
WO2012084423A3 (en) | Active ingredient combinations of glyceryl glucosides and one or more mild surfactants | |
ZA201009097B (en) | C-ring-substituted pregn-4-ene-21,17-carbolactone,and pharmaceutical preparations comprising the latter | |
WO2012021678A3 (en) | Isolated bacteria, methods for use, and methods for isolation | |
WO2011029102A3 (en) | Cd117+cells and uses thereof | |
WO2012036414A3 (en) | Cosmetic composition comprising a fermented soybean extract fraction as an active ingredient | |
EP2640953A4 (en) | Propellant compositions and methods of making and using the same | |
EP2509708B8 (en) | Silicon phosphate and membrane comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080048954.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10761069 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13392575 Country of ref document: US Ref document number: 484/MUMNP/2012 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2010761069 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010761069 Country of ref document: EP |